A Controlled N-of-1 Before-and-after Study to Determine Safety and Efficacy Triheptanoin in Patients With Glucose Transporter 1 Deficiency Syndrome
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 May 2018
Price : $35 *
At a glance
- Drugs Triheptanoin (Primary)
- Indications De Vivo disease
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 08 Aug 2016 According to an Ultragenyx Pharmaceutical media release, data from this study is expected in the second half of 2016.
- 30 May 2016 Status changed from recruiting to active, no longer recruiting.